Abstracts tagged "Still’s disease"

Abstract Number: 0829 • ACR Convergence 2022
Adult Onset Still’s Disease: A Retrospective Study of Objective Manifestations and Outcomes
Caroline Bui¹, Tim Collins², Kumar Venkat³, Napatkamon Ayutyanont², Kim Vickery⁴ and Scott Kubomoto², ¹Riverside Community Hospital/University of California Riverside, Riverside, CA, ²Riverside Community Hospital/University of California Riverside, Riverside, ³University of California Riverside/Riverside Community Hospital, Riverside, ⁴HCA Healthcare, Riverside
Background/Purpose: Adult Onset Still's Disease (AOSD) is a complex and rare inflammatory disease with life threatening complications. Due to its rarity and wide ranging clinical…
Abstract Number: 0863 • ACR Convergence 2022
Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study
Karen James¹, George Tomlinson², Tim Beukelman³, Laura Schanberg⁴, Anne Dennos⁵, VIncent Del Gaizo⁶, Marian Jelinek⁷, Erin Pfeifer⁸, Shalini Mohan⁹ and Yukiko Kimura¹⁰, ¹University of Utah, Salt Lake City, UT, ²University of Toronto, Toronto, ON, Canada, ³Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, ⁷Childhood Arthritis and Rheumatology Research Alliance (CARRA), Duke, ⁸Genentech, Englewood, NJ, ⁹Genentech, San Diego, ¹⁰Hackensack Meridian Health, New York, NY

Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a systemic autoinflammatory disease characterized by high fevers, rash and arthritis. Current treatment regimens often involve biologic (anti-IL-1…
Abstract Number: 0864 • ACR Convergence 2022
Baseline Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Esraa Eloseily¹, Min-Lee Chang², MaryEllen Riordan³, Alan Russell⁴, Marc Natter², Yukiko Kimura⁵ and Grant Schulert⁶, ¹Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Boston Children's Hospital, Boston, MA, ³Hackensack Meridian Health, Hackensack, NJ, ⁴Duke Clinical Research Institute, Duke, NC, ⁵Hackensack Meridian Health, New York, NY, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life threatening clinical problem, and currently affects as many as 1…
Abstract Number: 0867 • ACR Convergence 2022
Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration
Hiroto Nakano¹, Emily Shuldiner², Anne Hinks³, Marc Sudman⁴, Elaine Remmers⁵, Colleen Satorius⁶, Elizabeth Schmitz¹, Victoria Arthur⁷, Patricia Woo⁸, Alexei Grom⁹, Dirk Foell¹⁰, John Bohnsack¹¹, Marco Gattorno¹², Seza Ozen¹³, Sampath Prahalad¹⁴, Rae Yeung¹⁵, Elizabeth Mellins², Sheila Oliveira¹⁶, Jordi Antón¹⁷, Claudio Len¹⁸, Carol Lake¹⁹, Ly-Lan Bergeron²⁰, Michelle Millwood²¹, Estefania de los santos²¹, Mariana Correia Marques²², Juvenile Arthritis Consortium for the Immunochip²³, The Genomic Ascertainment Cohort Investigators²⁴, INCHARGE Consortium²⁵, Carl Langefeld²⁶, Susan Thompson²⁷, Wendy Thomson²⁸ and Michael Ombrello¹, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Stanford University, Stanford, CA, ³The University of Manchester, Manchester, United Kingdom, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵National Human Genome Research Institute, Bethesda, MD, ⁶NHGRI, NIH, Bethesda, MD, ⁷Boston Children's Hospital, Boston, MA, ⁸University College London, London, United Kingdom, ⁹Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰University Hospital Münster, Münster, Germany, ¹¹University of Utah, Salt Lake City, UT, ¹²Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹³Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁴Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ¹⁶Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Pediatric Rheumatology Department. Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat, Spain, ¹⁸Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁹NIH, Gaithersburg, MD, ²⁰NIH/NIAMS, Vienna, VA, ²¹NIAMS, NIH, Bethesda, MD, ²²National Institute of Arthritis and Musculoskeletal and Skin Diseases / Children`s National Hospital, Bethesda, MD, ²³Juvenile Arthritis Consortium for the Immunochip, Bethesda, MD, ²⁴The Genomic Ascertainment Cohort Investigators, Bethesda, MD, ²⁵International Childhood Arthritis Genetics Consortium, Bethesda, MD, ²⁶Wake Forest School of Medicine, Winston Salem, NC, ²⁷Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ²⁸Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare inflammatory disease that causes spiking fever, skin rash, chronic arthritis, and inflammation of the heart and…
Abstract Number: 0872 • ACR Convergence 2022
Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis
Holly Wobma¹, Maria Taylor², Ki Pui Lam¹, Helene Brown¹, Siobhan Case¹, Mia Chandler¹, Margaret Chang¹, Ezra Cohen¹, Megan Day-Lewis¹, Olha Halyabar¹, Jonathan Hausmann¹, Melissa Hazen³, Erin Janssen¹, Pui Lee¹, Mindy Lo¹, Esra Meidan¹, Jordan Roberts¹, Mary Beth F. Son¹, Robert Sundel¹, Fatma Dedeoglu¹, Peter Nigrovic¹, Alicia Casey⁴, Joyce Chang¹ and lauren henderson¹, ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Brighton, MA, ³Boston Children's Hospital, Boston, MA, ⁴Division of Pulmonary Medicine, Boston Children's Hospital, Boston, MA
Background/Purpose: Children with systemic juvenile idiopathic arthritis (sJIA) exposed to IL1/6 inhibitors may develop eosinophilia with an atypical rash, reportedly in association with HLA-DRB1*15:XX. There…
Abstract Number: 0195 • ACR Convergence 2021
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Louise GILLARD¹, Stéphane Mitrovic², Jacques Pouchot³, Fleur Cohen¹, Martin Michaud⁴, Heloise Reumaux⁵, Isabelle Kone-Paut⁶ and Bruno Fautrel⁷, ¹Pitié Salpêtrière Hospital, Paris, France, ²Pitié Salpêtrière Hospital - Institut Mutaliste Montsouris, Paris, France, ³AP-HP, RUEIL-MALMAISON, France, ⁴Joseph Ducuing Hospital, Toulouse, France, ⁵Jeanne de Flandre Hospital, Lille, France, ⁶APHP, Bicetre hospital, Le Kremlin bictre, France, ⁷Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: Excessive and inappropriate production of pro-inflammatory cytokines such as interleukin IL-1, IL-6 or IL-18, is a pathogenic cornerstone in adult and childhood onset Still’s…
Abstract Number: 0242 • ACR Convergence 2021
FiRst Line Options for Systemic JIA Treatment (FROST): Results from a Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Consensus Treatment Plan Observational Study
Timothy Beukelman¹, George Tomlinson², Peter Nigrovic³, Anne Dennos⁴, Vincent Del Gaizo⁵, Mary Ellen Riordan⁶, Laura Schanberg⁷, Shalini Mohan⁸, Erin Pfeifer⁹ and Yukiko Kimura¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Toronto, Toronto, ON, Canada, ³Boston Children's Hospital, Brookline, MA, ⁴Duke University, Durham, NC, ⁵Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁶Hackensack University Medical Center, Westwood, NJ, ⁷Duke University Medical Center, Durham, NC, ⁸Genentech, Inc., South San Francisco, CA, ⁹Genentech, Inc., Englewood, CO, ¹⁰Hackensack University Medical Center, New York, NY
Background/Purpose: The optimal initial treatment for systemic juvenile idiopathic arthritis (sJIA) is unclear. To further study the initial treatment of sJIA, the Childhood Arthritis and…
Abstract Number: 1100 • ACR Convergence 2021
Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease: A Case Series of 13 Patients
Stéphane Mitrovic¹, athénaïs Boucly², Estibaliz Lazaro³, Nicolas SCHLEINITZ⁴, Coralie Bloch-Queyrat⁵, Christine Christides⁶, Jacques Pouchot⁷, marc humbert², David Montani², laurent savale², Xavier Jaïs², Olivier Sitbon² and Bruno Fautrel⁸, ¹Pitié Salpêtrière Hospital - Institut Mutaliste Montsouris, Paris, France, ²Pneumology Department, Bicêtre Hospital, Assistance Publique – Hôpitaux de Paris, Kremlin-Bicêtre, France, ³Internal Medicine Department, CHU Bordeaux, Pessac, France, ⁴Internal Medicine Department, Hôpital Timone, APHM, Marseille, France, ⁵Internal Medicine Department, Avicennes Hospital, APHP, Bobigny, France, ⁶Internal Medicine Department, CH Avignon, Avignon, France, ⁷AP-HP, RUEIL-MALMAISON, France, ⁸Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: Pulmonary Arterial Hypertension (PAH) is a rare but potentially fatal complication of Adult-Onset Still's Disease (AOSD). To date, only isolated observations have been published.…
Abstract Number: 1548 • ACR Convergence 2021
Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California
Manushi Aggarwal and Marven Cabling, Loma Linda University Health, Redlands, CA
Background/Purpose: Q fever, an endemic disease in Southern California, is a zoonosis caused by Coxiella burnetii. The infection can present with multiple non-specific acute and chronic manifestations including fever, headache,…
Abstract Number: 1629 • ACR Convergence 2021
Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Vivian Saper¹, Sampath Prahalad², Scott Canna³, Rabheh Abdul-Aziz⁴, Marcela Alvarez⁵, Catherine Bingham⁶, Brigitte Bader-Meunier⁷, Imelda Balboni⁸, Roberta Berard⁹, Roxana Bolaria¹⁰, Alexis Boneparth¹¹, Alicia Casey¹², Elaine Cassidy¹³, Joyce C. Chang¹⁴, Michal Cidon¹⁵, Kathleen Collins¹⁶, Aileen M. Dickenson¹⁷, Graciela Espada⁵, Martha Fishman¹², Elaine Flanagan¹⁸, Timothy Hahn¹⁹, Ankur K. Jindal²⁰, Ozgur Kasapcopur²¹, Marisa Klein-Gitelman²², Timothy Klouda¹², Mikhail Kostik²³, Carol Lake²⁴, Mariana Marques²⁵, Michael Ombrello²⁶, Karen Onel²⁷, Omkar Phadke²⁸, Angelo Ravelli²⁹, Adam Reinhardt³⁰, Amanda D. Robinson³¹, Kelly Rouster-Stevens³², Nadine Saad²⁷, Grant Schulert³³, Susan Shenoi³⁴, Cory Stingl¹⁴, Anjali Sura³⁵, Melissa Tesher³⁶, Jessica Tibaldi³⁷, Kathryn Torok³⁸, Cathy Tsin³⁹, Natalia Vasquez-Canizares⁴⁰, D. Sofia Villacis-Nunez⁴¹, Ben Whitehead⁴², Holly Wobma¹², Lawrence Zemel⁴³ and Elizabeth Mellins¹, ¹Stanford University, Stanford, CA, ²Emory + Children's Pediatric Institute, Atlanta, GA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University at Buffalo, Buffalo, NY, ⁵Hospital de Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina, ⁶Penn State Children's Hospital, Allentown, PA, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Stanford University, Palo Alto, CA, ⁹London Health Sciences Centre, London, ON, Canada, ¹⁰Self, Victoria, BC, Canada, ¹¹Columbia University Medical Center, New York, NY, ¹²Boston Children's Hospital, Boston, MA, ¹³University of Pittsburgh Medical Center Medical Education, Pittsburgh, PA, ¹⁴Children's Hospital of Phildelphia, Philadelphia, PA, ¹⁵Children's Hospital Los Angeles, Los Angeles, CA, ¹⁶LeBonheur Children's Hospital, Memphis, TN, ¹⁷Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁸Emory University and Children's Healthcare of Atlanta, Atlanta, GA, ¹⁹Penn State Childrens Hospital, Hershey, PA, ²⁰Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ²²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴National Institutes of Health, Gaithersburg, MD, ²⁵UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²⁷Hospital for Special Surgery, New York, NY, ²⁸EMORY, Atlanta, GA, ²⁹Istituto Giannina Gaslini, Genoa, Italy, ³⁰Boys Town National Research Hospital, Omaha, NE, ³¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁴Seattle Children's Hospital, Seattle, WA, ³⁵SUNY Upstate Medical University, Syracuse, NY, ³⁶University of Chicago, Chicago, IL, ³⁷IRCSS Istituto G. Gaslini University of Genoa, Genoa, Italy, ³⁸University of Pittsburgh, Pittsburgh, PA, ³⁹Stanford University, Stanford, ⁴⁰Children's Hospital at Montefiore, Bronx, NY, ⁴¹Children's Healthcare of Atlanta - Emory University, Atlanta, GA, ⁴²Queensland Children's Hospital, Brisbane, Australia, ⁴³CCMC, Hartford, CT
Background/Purpose: Severe delayed hypersensitivity reactions (DHR) are under-recognized in inflammatory conditions, particularly drug reaction with eosinophilia and systemic symptoms (DRESS). Previous work has shown this…
Abstract Number: 1950 • ACR Convergence 2020
Elevated Serum Gasdermin D N-terminal Implicates Macrophage Pyroptosis in Adult-onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis
Hideto Nagai¹, Yohei Kirino², Hiroto Nakano³, Yosuke Kunishita¹ and Michael Ombrello⁴, ¹Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³NIAMS, NIH, Bethesda, ⁴Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD
Background/Purpose: Elevation of serum IL-18 in adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) suggests involvement of one or more inflammasome in these…
Abstract Number: 0098 • ACR Convergence 2020
CCL2 and CCR2 in Adult Onset Still’s Disease
Ju-Yang Jung¹, Ji-Won Kim¹, Chang-Hee Suh¹ and Hyoun-Ah Kim¹, ¹Ajou university school of medicine, Suwon, Republic of Korea
Background/Purpose: Adult onset Still's disease (AOSD) is a rare systemic inflammatory disease characterized by a high spiking fever, evanescent rash, arthralgia, generalized lymphadenopathy, and leukocytosis.…
Abstract Number: 0174 • ACR Convergence 2020
Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis
Emily Shuldiner¹, Elaine Remmers², Miranda Marion³, Marc Sudman⁴, Colleen Satorius⁵, Patricia Woo⁶, Sampath Prahalad⁷, Carl Langefeld⁸, Susan Thompson⁹, Wendy Thomson¹⁰ and Michael Ombrello¹¹, ¹NIAMS, NIH, Bethesda, ²National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ³Wake Forest School of Medicine, Winston-Salem, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵NHGRI, NIH, Bethesda, ⁶Great Ormond Street Hospital, London, United Kingdom, ⁷Emory + Children's Pediatric Institute, Atlanta, GA, ⁸Wake Forest School of Medicine, Winston Salem, NC, ⁹Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ¹⁰Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe, potentially lethal inflammatory condition. It accounts for a disproportionate share of morbidity and mortality among childhood…
Abstract Number: 1148 • ACR Convergence 2020
The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA
Arjen Leek¹, Jordi Anton², Tadej Avcin³, Fabrizio De Benedetti⁴, Victor Boom¹, Claudia Bracaglia⁵, Paul Brogan⁶, Tamas Constantin⁷, Alessandro Consolaro⁸, Pavla Dolezalova⁹, Despina Eleftheriou¹⁰, Helen Foster¹¹, Claas Hinze¹², Isabelle Koné-Paut¹³, Kirsten Minden¹⁴, Francesca Minoia¹⁵, Pierre Quartier¹⁶, Angelo Ravelli⁸, Nicolino Ruperto¹⁷, Joost Swart¹⁸, Yosef Uziel¹⁹, Helmut Wittkowski²⁰, Carine Wouters²¹, Mojca Zajc Avramovitz²², Nico Wulffraat¹⁸ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Sant Joan de Déu Hospital, Madrid, Spain, ³Ljubljana University Medical Centre, Ljubljana, Slovenia, ⁴Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁵Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁶UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁷Semmelweiss University Hospital, Budapest, Hungary, ⁸Università degli Studi di Genova, Genoa, Italy, ⁹University Hospital Prague, Prague, Czech Republic, ¹⁰UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ¹¹Newcastle University, Newcastle upon Tyne, United Kingdom, ¹²University Hospital M�nster, M�nster, Germany, ¹³Necker Hospital, Paris, France, ¹⁴Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ¹⁶Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ¹⁷Istituto Giannina Gaslini, Genova, Italy, ¹⁸IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, ¹⁹Meir Medical Center, Kfar Saba, Israel, ²⁰University Hospital Muenster, Muenster, Germany, ²¹University Hospital Leuven, Leuven, Belgium, ²²University Hospital Ljubljana, Ljubljana, Slovenia
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex auto-inflammatory disease with significant morbidity including fever, rash, serositis and articular problems. With the availability…
Abstract Number: 1633 • ACR Convergence 2020
A Randomized, Double-Blind, Placebo-Controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
Laura Schanberg¹, Peter Nigrovic², Ashley Cooper³, Winn Chatham⁴, Shoghik Akoghlanian⁵, Namrata Singh⁶, C. Egla Rabinovich⁷, Akaluck Thatayatikom⁸, Alysha Taxter⁹, Jonathan Hausmann¹⁰, Milan Zdravkovic¹¹, Sven Ohlman¹¹, Henrik Andersson¹¹, Susanna Cederholm¹¹, Gunilla Huledal¹¹, Rayfel Schneider¹² and Fabrizio De Benedetti¹³, ¹Duke University Medical Center, Durham, NC, ²Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ³Children's Mercy Kansas City, Kansas City, MO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Nationwide Children’s Hospital, Columbus, ⁶University of Washington, Bellevue, WA, ⁷Duke University Hospital, Durham, NC, ⁸Department of Pediatrics, University of Florida, Gainesville, FL, ⁹Wake Forest Baptist Medical Center, Winston-Salem, ¹⁰Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹¹Sobi, Stockholm, Sweden, ¹²University of Toronto, The Hospital for Sick Children, Toronto, Canada, ¹³Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: Still’s disease, including both systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD), is a rare systemic auto-inflammatory disorder associated with an activated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].